MARKET WIREYahoo Finance UK • 1d ago
ABIVAX Société Anonyme (0RA9.L) stock price, news, quote and historyYahoo Finance UK report covering Abivax SA (ABVX) market action, institutional positioning, and fundamental catalysts.
Why ABVX Stock dropped -2.77% Today — RQD Quant Desk Flash
$86.59 -2.77% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $85.99
Abivax SA (ABVX) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $7.56B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ABVX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ABVX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Abivax SA (NASDAQ: ABVX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $86.59 (-2.77% 1D, market cap $7.56B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, ABVX ranks #210 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ABVX compare to AXSM and ALKS in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABVX carries a Roarable D+ (54/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, AXSM (Axsome Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -21.9%, cap $7.57B) and ALKS (Alkermes plc) posts a B+ grade (78/100 RQD, P/E 31.5x, ROIC 14.0%, cap $7.61B). Among the 5-stock peer group, ALKS leads on earnings multiple (31.5x) while AMRX leads on capital efficiency (14.1% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ABVX?
▼
For Abivax SA (ABVX), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs and sector rank #210 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $85.99 (-0.69%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 4.2% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-1.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABVX)Realized 20D OHLCV Swing Band: ±8.3%
Deterministic 5-Pillar Attribution (54/100 Composite)
🔍 WHY ABVX SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (30% of score)
Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+12/20 pts (22% of score)
SEC Form 4 / 13F Thermometer: 60% Net Buy • Cannibal Buyback (-1.24% YoY Shares)
▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$87.98+6.3% Next Q
62
Q2 (-2Q)Grade C$93.49-3.9% Next Q
59
Q3 (-1Q)Grade C$89.84-3.6% Next Q
57
CurrentGrade D+$86.59-0.7% Hist 90D α
54
Trajectory: C+ (62) → D+ (54)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ABVX Turnaround Squeeze
While ABVX currently carries a cautious 54/100 (D+) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Clean SEC annual filing review with no major hidden accounting time-bombs.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($98.45) and Max Pain ($90.92) forces dealer call-delta covering toward $156.27.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-1.24% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABVX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ABVX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ABVX Stock dropped -2.77% Today — RQD Quant Desk Flash
Abivax SA (ABVX) dropped -2.77% to $86.59, trading at 21% of its 52-week range ($69.81 – $148.83). Stretched risk/reward at 33x P/E (10% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 21% of its 52-week range ($69.81 – $148.83) with RSI-14 at 41 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±8.3% around $86.59 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 52% gross margin and $167.0M annual free cash flow.
Live ABVX Headlines & Catalysts
MARKET WIREMoomoo • 1d ago
ABVX 261030 65.00C (ABVX261030C65000) Stock Community & DiscussionMoomoo report covering Abivax SA (ABVX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Vilga Financial Planning LLC Acquires 22,000 Shares of Abivax SA Sponsored ADR $ABVXMarketBeat report covering Abivax SA (ABVX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
676,589 Shares in Abivax SA Sponsored ADR $ABVX Acquired by Two Seas Capital LPMarketBeat report covering Abivax SA (ABVX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMoomoo • 1d ago
ABVX 261030 65.00C (ABVX261030C65000) Stock Options Chain & PriceMoomoo report covering Abivax SA (ABVX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.dars.gov.et/ • 1d ago
Abivax SA (ABVX) Holds Near $87 as Shares Edge Higher Within a Balanced Trading Range - Daily Profilehttps://www.dars.gov.et/ report covering Abivax SA (ABVX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Abivax SA Sponsored ADR (NASDAQ:ABVX) Stock Now Rated "Moderate Buy" by Sell-Side AnalystsMarketBeat report covering Abivax SA (ABVX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Abivax (NASDAQ:ABVX) Given "Buy" Rating at GuggenheimMarketBeat report covering Abivax SA (ABVX) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 18h ago
Abivax to Participate in Upcoming Fall Investor ConferencesAbivax to Participate in Upcoming Fall Investor Conferences PARIS, France – November 2, 2026 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage b
MARKET WIREBenzinga • 11d ago
10 Health Care Stocks Whale Activity In Today’s SessionThis whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABVX)
- ✓Walkthrough of ABVX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ABVX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.07%▼ DESCENDING CHANNEL
2026-11-03O $89.06H $89.06L $86.59C $86.59VOL 843.4K
RES: $96.85SUP: $71.16SMA50: $98.45SMA200: $113.7
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ABVX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
25.3%/yr Implied 5Y Growth
vs. +8.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on ABVX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ABVX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ABVX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABVX)
Health Care Rank #210 of 1015
⚔️ AXSM vs ABVX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ABVX vs. AXSM, ALKS, AMRX, KNSA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Abivax SA (ABVX) ranks #210 by composite RQD confidence (54/100, grade D+) and #129 by equity capitalization ($7.56B). Within this direct 5-issuer industry benchmark cohort, ALKS leads on earnings valuation at 31.5x trailing P/E, while AMRX leads on capital efficiency and profitability with 14.1% ROIC and 36.9% gross margin. ALKS currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with ABVX at 54/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ABVX
ACTIVE
Abivax SA | D+ | 54/100 | 32.8x | — | 9.9% | -2.77% | $7.56B | Benchmark Subject |
| AXSM Axsome Therapeutics Inc. | D- | 35/100 | — | — | -21.9% | +0.68% | $7.57B | /axsm-vs-abvx → |
| ALKS Alkermes plc | B+ | 78/100 | 31.5x | 86.7% | 14.0% | -0.07% | $7.61B | /alks-vs-abvx → |
| AMRX Amneal Pharmaceuticals Inc. | B- | 71/100 | 103.2x | 36.9% | 14.1% | +0.75% | $7.49B | /amrx-vs-abvx → |
| KNSA Kiniksa Pharmaceuticals International plc (Class A) | B- | 71/100 | 129.9x | 88.5% | 9.9% | -5.45% | $7.25B | /knsa-vs-abvx → |
2. ABVX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTAbivax SA (ABVX) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $7.56B, trailing P/E of 32.8x, forward P/E of 30.5x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.
3. ABVX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ABVX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Abivax SA (NASDAQ: ABVX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $86.59 (-2.77% 1D, market cap $7.56B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, ABVX ranks #210 in composite RQD confidence.
How does ABVX compare to AXSM and ALKS in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABVX carries a Roarable D+ (54/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, AXSM (Axsome Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -21.9%, cap $7.57B) and ALKS (Alkermes plc) posts a B+ grade (78/100 RQD, P/E 31.5x, ROIC 14.0%, cap $7.61B). Among the 5-stock peer group, ALKS leads on earnings multiple (31.5x) while AMRX leads on capital efficiency (14.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ABVX?
For Abivax SA (ABVX), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs and sector rank #210 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ABVX trading relative to its 50-day, 200-day, and 52-week technical levels?
ABVX last traded at $86.59 (-2.77% on volume of 843,441 shares), positioning the stock -12.05% below its 50-day simple moving average ($98.45) and -23.82% below its 200-day simple moving average ($113.66). Across its 52-week range of $69.81 to $148.83, ABVX sits at the 21.2% percentile with a 14-day RSI of 41.0 (NEUTRAL RANGE) and an implied next-earnings move of ±8.3% ($79.40 to $93.78).
ROARABLE RATING BRIEF • RQD 54/100 (D+)
✓ SEC XBRL & RQD VERIFIED
ABVX — Abivax SA: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03
1. Roarable Rating Brief: What This Means to a Prospective Investor
Abivax SA (ABVX) earns a live Roarable RQD composite score of 54/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $86.59 (-2.77% 1D, market capitalization $7.56B).
- Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of 9.9%, gross margin of —, operating margin of 13.9%, and free cash flow yield of 2.21%.
- Whale 13F & Options Flow (5/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (10/20) + Forensic Balance Sheet (16/20): Incorporates a 1.05x equity beta, Altman Z-Score of 3.74, Piotroski F-Score of 8/9, and Debt/Equity of 0.39x.
2. Business Model, Unit Margins & SEC Financial Trajectory
Abivax SA (ABVX) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..8B.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D+ • RQD 54/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of 2.21% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $69.81 – $148.83 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 32.8x trailing P/E and 21.0x EV/EBITDA against 13.9% operating margins and a 1.05x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be assessed from the source data.
- Key Question #1: Can ABVX sustain or expand its 13.9% operating margin and 9.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Will free cash flow conversion (2.21% FCF yield) strengthen balance-sheet liquidity (Altman Z-Score 3.74) toward the $148.83 52-week high?
- Key Question #3: How sensitive is ABVX's 30.5x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.05x)?
ABVX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Abivax SA (ABVX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance UK • 1d ago
ABIVAX Société Anonyme (0RA9.L) stock price, news, quote and history Yahoo Finance UK report covering Abivax SA (ABVX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Moomoo • 1d ago
ABVX 261030 65.00C (ABVX261030C65000) Stock Community & Discussion Moomoo report covering Abivax SA (ABVX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Vilga Financial Planning LLC Acquires 22,000 Shares of Abivax SA Sponsored ADR $ABVX MarketBeat report covering Abivax SA (ABVX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
676,589 Shares in Abivax SA Sponsored ADR $ABVX Acquired by Two Seas Capital LP MarketBeat report covering Abivax SA (ABVX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Moomoo • 1d ago
ABVX 261030 65.00C (ABVX261030C65000) Stock Options Chain & Price Moomoo report covering Abivax SA (ABVX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago
Abivax SA (ABVX) Holds Near $87 as Shares Edge Higher Within a Balanced Trading Range - Daily Profile https://www.dars.gov.et/ report covering Abivax SA (ABVX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Abivax SA Sponsored ADR (NASDAQ:ABVX) Stock Now Rated "Moderate Buy" by Sell-Side Analysts MarketBeat report covering Abivax SA (ABVX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Abivax (NASDAQ:ABVX) Given "Buy" Rating at Guggenheim MarketBeat report covering Abivax SA (ABVX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ABVX Bull vs. Bear Conversation Board — What's Your Call at $86.59?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ABVX 🐻 33% BEARISH CONVICTION
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH
🎯 Target: $104.77 (+21.0%)
📌 Pinned Debate Forensic balance sheet scores 16/20 with Altman Z 3.74, Piotroski F 8/9, and Debt/Equity 0.39, a strong foundation for the stock.
Forensic balance sheet scores 16/20 with Altman Z 3.74, Piotroski F 8/9, and Debt/Equity 0.39, a strong foundation for the stock.. When you look under the hood at ABVX, Fundamental Cash Engine is 11/20 with 0.0% gross margins and 9.9% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (5/20) has been quietly accumulating below $148.83. My 12M target is $104.77.
CapAlloc_Nerd 🐂 BULL
@MultipleCompression Fair point on 32.8x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH
🎯 Target: $67.54 (-22.0%)
Spot @ $86.59 Whale 13F flow scores only 4/20 and FCF yield is 2.21% against a P/E TTM of 32.8, leaving weak institutional support and thin cash retu
Careful chasing ABVX at $86.59. Whale 13F flow scores only 4/20 and FCF yield is 2.21% against a P/E TTM of 32.8, leaving weak institutional support and thin cash returns for the valuation.. Gross margin is 0.0%, but operating margin is 13.9%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $67.54 on multiple compression.